Live Breaking News & Updates on ப்ரிந்ஸிபல் கணக்குவைப்பு முறை
Stay updated with breaking news from ப்ரிந்ஸிபல் கணக்குவைப்பு முறை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator Good morning, ladies and gentlemen. Welcome to today s Ruth s Hospitality Group First Quarter 2021 Earnings Conference Call. [Operator Instructions] As a reminder, today s conference call is being recorded. I would now like to turn the conference over to Kristy Chipman, Chief Financial Officer. Please go ahead. Kristy Chipman Executive Vice President, Chief Financial Officer & Principal Accounting Officer Thank you, Daryl, and good morning, everyone. Joining me on the call today is Cheryl Henry, our President and Chief Executive Officer. Before we begin, I d first like to remind you that part of our discussion today will include forward-looking statements. These statements are not guarantees of our future performance, and therefore, undue reliance should not be placed upon them. We would also encourage you to refer to the Investor Relations section of our website at rhgi.com as well as the SEC s website at sec.gov for copies of today s earnings press re ....
Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to Agenus First Quarter 2021 Conference Call and Webcast. [Operator Instructions] Please note that this event is being recorded and may be used in future Agenus promotional material. I would now like to turn the conference over to Jan Medina, Director of Investor Relations. Jan, please go ahead. Jan Medina Director, Investor Relations Thank you, Rebecca and thank you, all, for joining us today. Today s call is being webcast and will be available on our website for replay. I would like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and timelines, as well as timelines for data release and partnership opportunities. These statements are subject to risks and uncertainties and we refer you to our SEC filings for more details on these risks. As a reminder, this call is being r ....
Operator Good day, and thank you for standing by. Welcome to the Concert Pharmaceuticals First Quarter 2021 Financial Results Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Justine Koenigsberg. Please go ahead. Justine E. Koenigsberg Senior Vice President of Corporate Communications and Investor Relations Good morning, and welcome to Concert Pharmaceuticals First Quarter 2021 Investor Update. Our prepared comments today will be brief, so we can jump right into the Q&A portion of the call. Roger Tung, our CEO, will provide the CTP-543 key highlights; and then Marc Becker, our CFO, will walk you through the first quarter financials. We will then be joined by Nancy Stuart, our Chief Operating Officer; and Jim Cassella, our Chief Development Officer, for the Q&A portion of the call. As a reminder, today s discussion will include forward-looking statements about our future expectations, plans and prospects ....
Welcome to CalAmp s Fourth Quarter 2021 Financial Results Conference Call. [Operator Instructions] I would now like to introduce your host for today s conference call, Joel Achramowicz, Managing Director of the Shelton Group, CalAmp s Investor Relations firm. Joel, you may begin. Joel Achramowicz Managing Director Good afternoon, and welcome to CalAmp s Fiscal Fourth Quarter 2021 Financial Results Conference Call. I m Joel Achramowicz, Managing Director of Shelton Group, CalAmp s Investor Relations firm. With us today are CalAmp s President and Chief Executive Officer, Jeff Gardner; and Chief Financial Officer, Kurt Binder. Before we begin, I d like to remind you that this call may contain forward-looking statements. While these forward-looking statements reflect CalAmp s best current judgment, they re subject to risks and uncertainties that could cause actual results to differ materially from those implied by these forward-looking projections. These risk factor ....
LAVA Therapeutics BV: LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCEs) to transform cancer therapy, today announced that Karen J. Wilson has been appointed to its Board of Directors and as chair of its Audit Committee. Ms. Wilson brings more than three decades of finance and leadership experience in the life sciences industry. I am delighted to welcome Karen to our Board of Directors, said Stephen Hurly, Chief Executive Officer and President. She joins us at an exciting time for our company as our first gamma-delta bsTCE candidates progress towards the clinic. Her deep experience leading finance organizations across both clinical- and commercial-stage public life science companies will be invaluable to LAVA as we advance our pipe ....